表皮生长因子受体抑制剂联合放疗治疗头颈部鳞癌的研究进展
摘要
头颈部鳞癌(squamous cell carcinoma of the head and neck ,SCCHN)就诊时约60%为局部晚期。
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2012年第6期583-586,共4页
Chinese Journal of Radiation Oncology
二级参考文献23
-
1[1]Rubin-Grandis J,Melhem MF,Gooding WE,et al.Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival[J].J Natl Cancer Inst,1998,90(11):824-832.
-
2[2]Mendelsohn J,Baselga J.Epidermal growth factor receptor targeting in cancer[J].Semin Oncol,2006,33(4):369-385.
-
3[3]Astsaturov I,Cohen RB,Harari PM.EGFR-targeting monoclonal antibodies in head and neck cancer[J].Curr Cancer Drug Targets,2006,6(8):691-710.
-
4[4]Ravindranath N,Wion D,Brachet P,et al.Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate[J].J Androl,2001,22(3):432-443.
-
5[5]Viloria-Petit A,Crombet T,Jothy S,et al.Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo:a role for altered tumor angiogenesis[J].Cancer Res,2001,61(13):5090-5101.
-
6[6]Viloria-Petit AM,Kerbel RS.Acquired resistance to EGFR inhibitors:mechanisms and prevention strategies[J].Int J Radiat Oncol Biol Phys,2004,58(3):914-926.
-
7[7]Ciardiello F,Bianco R,Caputo R,et al.Antitumor activity of ZD6474,a vascular endothelial growth factor receptor tyrosine kinase inhibitor,in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy[J].Clin Cancer Res,2004,10(2):784-793.
-
8[8]Vallbohmer D,Zhang,W,Gordon,M,et al.Molecular determinants of cetuximab efficacy[J].J Clin Oncol,2005,23(15):3536-3544.
-
9[9]Chakravarti A,Loeffler JS,Dyson NJ.Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling[J].Cancer Res,2002,62(1):200-207.
-
10[10]Lu Y,Zi X,Zhao Y,et al.Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)[J].J Natl Cancer Inst,2001,93(24):1852-1857.
共引文献93
-
1陈亚军,王佩国.头颈癌患者肌肉减少症的诊断与干预研究进展[J].国际生物医学工程杂志,2022,45(5):453-457.
-
2李德锐,陈志坚,陈创珍,陈建洲,李东升,周明镇,林志雄.3227例鼻咽癌患者放射治疗后生存结果分析[J].中国肿瘤,2010,19(5):348-350. 被引量:3
-
3费建东,王晓寅,薄爱华,吴力娟,朱玉平,刘志峰.胃癌中MGMT和EGFR表达及其意义[J].现代肿瘤医学,2010,18(7):1346-1348. 被引量:2
-
4无.头颈部肿瘤综合治疗专家共识[J].中华耳鼻咽喉头颈外科杂志,2010,45(7):535-541. 被引量:56
-
5郑苏.EGFR酪氨酸激酶抑制剂的研究进展[J].现代医药卫生,2010,26(20):3103-3105. 被引量:2
-
6花永虹(综述),马胜林(审校),傅真富(审校).头颈部癌的靶向治疗进展[J].国际肿瘤学杂志,2010,37(11):845-848.
-
7王昱,卢仲毅,许峰,朱宇迪,朱宇熹.羟基脲对体外Hela细胞周期同步化作用的研究[J].重庆医学,2010,39(24):3331-3332. 被引量:3
-
8黄辉,徐震纲,唐平章,刘绍严,吴跃煌,王晓雷.梨状窝癌术前同步放化疗对手术并发症影响的临床研究[J].中华耳鼻咽喉头颈外科杂志,2011,46(2):114-117. 被引量:10
-
9易俊林,高黎,徐震纲,黄晓东,刘绍严,罗京伟,王晓雷,李素艳,肖建平,张世平,王凯,曲媛,徐国镇.术前同期放化与单纯放疗局部晚期头颈部鳞癌的Ⅲ期临床研究[J].中华放射肿瘤学杂志,2011,20(5):363-367. 被引量:9
-
10金厅,王芳,胡伟汉,蔡修宇,葛楠,徐韬,林辉.下咽鳞癌中HIF-1α与VEGF表达的临床治疗意义[J].中华放射肿瘤学杂志,2011,20(5):385-389. 被引量:1
-
1吴润叶,高黎.头颈部局部晚期鳞癌的同期放化疗和靶向治疗进展[J].中华放射肿瘤学杂志,2011,20(4):325-329. 被引量:1
-
2吴润叶,高黎.头颈部鳞状细胞癌治疗进展[J].癌症进展,2010,8(1):43-48. 被引量:3
-
3周亚娟,周晓艺.西妥昔单抗在头颈部肿瘤临床应用进展[J].药品评价,2012,9(15):41-45.
-
4黄碧有,吴永忠.放射治疗中的分割模式进展[J].四川肿瘤防治,1998,11(2):49-51.
-
5Danyel Elias da Cruz Perez.Prognostic factors in head and neck ACC[J].中国口腔颌面外科杂志,2008,6(B05):33-33.
-
6杜立法,王俊杰.表皮生长因子受体靶向治疗头颈部鳞状细胞癌的基础研究[J].癌症进展,2012,10(4):355-359.
-
7陈斌,陶磊,周梁.趋化因子及其受体与头颈部鳞状细胞癌的发展演进[J].临床耳鼻咽喉头颈外科杂志,2009,23(15):718-720. 被引量:3
-
8任庆兰,吴永忠,陈晓品,戴晓波.唑来膦酸联合单次或多次分割放射治疗转移性骨痛的临床分析[J].第三军医大学学报,2008,30(2):176-178. 被引量:2
-
9许光,杨旭,宋丽萍,刘锦东,张奎权.非小细胞肺癌脑转移患者两种放疗分割模式及疗效评估[J].中国医学影像学杂志,2013,21(5):326-329.
-
10王伟,王捷.乳腺癌不同放疗分割模式的研究进展[J].肿瘤预防与治疗,2015,28(3):174-178. 被引量:6